A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple
myeloma (MM) and what side effects (unwanted effects) may occur.
The study will have three parts. In the first part, participants get SEA-BCMA by itself. This
part of the study will find out how much SEA-BCMA should be given for treatment and how
often. It will also find out how safe the treatment is and how well it works.
In the second part of the study, participants will get SEA-BCMA and dexamethasone. In the
third part, participants will get SEA-BCMA, dexamethasone, and either pomalidomide or
nirogacestat. Dexamethasone and pomalidomide are both drugs that can be used to treat
multiple myeloma. Nirogacestat is an experimental drug that can be used with SEA-BCMA to
treat multiple myeloma. These parts of the study will find out whether these drugs are safe
when used together.